Cyxone files patent application with potential to extend market exclusivity of the drug candidate Rabeximod
Cyxone (publ) today announces that the company has filed a new patent application for Rabeximod with patent authorities in key strategic territories. Approval of this new patent application on these markets, in conjunction with four additional patents filed during the period 2020–2021, will strengthen the intellectual property portfolio for Rabeximod and elongate the market exclusivity period until at least 2043.Rabeximod is a well-tolerated, orally available Phase 2 drug candidate that selectively targets the inflammatory macrophage – the central orchestrator of the inflammatory process.